<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">54556</article-id><article-id pub-id-type="doi">10.7554/eLife.54556</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Advance</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group></article-categories><title-group><article-title>Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-168968"><name><surname>Jarosz-Griffiths</surname><given-names>Heledd H</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5154-4815</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-176095"><name><surname>Scambler</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146094"><name><surname>Wong</surname><given-names>Chi H</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2108-1615</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146092"><name><surname>Lara-Reyna</surname><given-names>Samuel</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9986-5279</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146095"><name><surname>Holbrook</surname><given-names>Jonathan</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-41308"><name><surname>Martinon</surname><given-names>Fabio</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-6969-822X</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146096"><name><surname>Savic</surname><given-names>Sinisa</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7910-0554</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169044"><name><surname>Whitaker</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169046"><name><surname>Etherington</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169047"><name><surname>Spoletini</surname><given-names>Giulia</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-169045"><name><surname>Clifton</surname><given-names>Ian</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-168975"><name><surname>Mehta</surname><given-names>Anil</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-146106"><name><surname>McDermott</surname><given-names>Michael F</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1015-0745</contrib-id><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-146097"><name><surname>Peckham</surname><given-names>Daniel</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7723-1868</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><institution content-type="dept">Leeds Institute of Medical Research</institution>, <institution>University of Leeds</institution>, <addr-line><named-content content-type="city">Leeds</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff2"><institution content-type="dept">Leeds Institute of Rheumatic and Musculoskeletal Medicine</institution>, <institution>University of Leeds</institution>, <addr-line><named-content content-type="city">Leeds</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff3"><institution content-type="dept">Department of Biochemistry</institution>, <institution>University of Lausanne</institution>, <addr-line><named-content content-type="city">Epalinges</named-content></addr-line>, <country>Switzerland</country></aff><aff id="aff4"><institution content-type="dept">Adult Cystic Fibrosis Unit</institution>, <institution>St James's University Hospital</institution>, <addr-line><named-content content-type="city">Leeds</named-content></addr-line>, <country>United Kingdom</country></aff><aff id="aff5"><institution content-type="dept">Division of Medical Sciences</institution>, <institution>University of Dundee</institution>, <addr-line><named-content content-type="city">Dundee</named-content></addr-line>, <country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-41027"><name><surname>van der Meer</surname><given-names>Jos WM</given-names></name><role>Reviewing editor</role><aff><institution>Radboud University Medical Centre</institution>, <country>Netherlands</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>D.G.Peckham@leeds.ac.uk</email> (DP);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>02</day><month>03</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e54556</elocation-id><history><date date-type="received"><day>03</day><month>01</month><year>2020</year></date><date date-type="accepted"><day>28</day><month>02</month><year>2020</year></date></history><permissions><copyright-statement>© 2020, Jarosz-Griffiths et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Jarosz-Griffiths et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-54556-v1.pdf"/><abstract><p>Previously we showed that serum and monocytes from patients with CF exhibit an enhanced NLRP3-inflammasome signature with increased IL-18, IL-1β, caspase-1 activity and ASC speck release (Scambler et al., eLife 2019). Here we show that CFTR modulators down regulate this exaggerated proinflammatory response following LPS/ATP stimulation. <italic>In vitro</italic> application of ivacaftor/lumacaftor or ivacaftor/tezacaftor to CF monocytes showed a significant reduction in IL-18, whereas IL-1β was only reduced with ivacaftor/tezacaftor. Thirteen adults starting ivacaftor/lumacaftor and eight starting ivacaftor/tezacaftor were assessed over three months. Serum IL-18 and TNF decreased significantly with treatments, but IL-1β only declined following ivacaftor/tezacaftor. In (LPS/ATP-stimulated) PBMCs, IL-18/TNF/caspase-1 were all significantly decreased and IL-10 was increased with both combinations. Ivacaftor/tezacaftor alone showed a significant reduction in IL-1β and pro-IL-1β mRNA. This study demonstrates that these CFTR modulator combinations have potent anti-inflammatory properties, in addition to their ability to stimulate CFTR function, which could contribute to improved clinical outcomes.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000292</institution-id><institution>Cystic Fibrosis Trust</institution></institution-wrap></funding-source><award-id>SRC009</award-id><principal-award-recipient><name><surname>Peckham</surname><given-names>Daniel</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf1"><p>The authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Human subjects: Patients with CF and healthy controls (HC) were recruited from the Department of Respiratory Medicine and Research laboratories at the Wellcome Trust Benner Building at St James's Hospital. The study was approved by Yorkshire and The Humber Research Ethics Committee (17/YH/0084). Informed written consent was obtained from all participants at the time of the sample collection.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files.</p></sec><supplementary-material><ext-link xlink:href="elife-54556-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>